Global AI-based Clinical Trials Solution Provider Market is valued at approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2028. The emergence of artificial intelligence (AI) in the research and development activities in clinical trials aids in improving operational competence, minimizing costs, and boosting drug discovery. AI technology integrated with big data helps in solving various key clinical trial challenges, which is leading the market growth. Factors such as the increase in the number of clinical studies, and growing penetration of the AI-based platforms for enhancing efficiency and productivity of trials at many stages, coupled with the development of the pharmaceutical and CROs sector are impelling the growth of the global market. For instance, as per a Statista report, in 2018, the total number of registered clinical studies worldwide was recorded at 293,259 and the figure is constantly rising and reach 409,300 studies by 2022. Accordingly, the rising clinical studies are positively influencing the growth of the AI-based Clinical Trials Solution Provider market across the globe. However, the lack of AI accuracy in clinical practices and the imposition of several stringent regulations on the approval of AI-based clinical trials hinders the growth of the market over the forecast period of 2022-2028. Also, rising R&D investments in various therapeutic areas and growing awareness and diversified applications of artificial intelligence (AI) in the field of clinical trials are anticipated to act as catalyzing factors for the market demand during the forecast period.
The key regions considered for the global AI-based Clinical Trials Solution Provider Market study include: Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the availability of favorable government policies and the rising presence of a number of AI-based start-ups. Whereas, Asia-Pacific is anticipated to exhibit the highest CAGR over the forecast period 2022-2028. Factors such as the growing adoption of AI-based tools, rising patient pool, as well as, increasing prevalence of various diseases, would create lucrative growth prospects for the AI-based Clinical Trials Solution Provider Market across the Asia-Pacific region.
Major market players included in this report are:
- Unlearn.AI, Inc.
- Saama Technologies
- Antidote Technologies, Inc.
- Innoplexus
- Mendel.ai
- Median Technologies
- Symphony AI
- BioAge Labs, Inc.
- AiCure, LLC
- Halo Health Systems
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Clinical Trial Phase:
- Phase-I
- Phase-II
- Phase-III
By Application:
- Oncology
- Cardiovascular Diseases
- Neurological Diseases or Conditions
- Infectious Diseases
- Others
By End-use:
- Pharmaceutical Companies
- Academia
- Others
By Region:
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
Furthermore, years considered for the study are as follows:
- Historical year - 2018, 2019, 2020
- Base year - 2021
- Forecast period - 2022 to 2028
Target Audience of the Global AI-based Clinical Trials Solution Provider Market in Market Study:
- Key Consulting Companies & Advisors
- Large, medium-sized, and small enterprises
- Venture capitalists
- Value-Added Resellers (VARs)
- Third-party knowledge providers
- Investment bankers
- Investors
Table of Contents
Chapter 1. Executive Summary
- 1.1. Market Snapshot
- 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Million)
- 1.2.1. AI-based Clinical Trials Solution Provider Market, by Region, 2020-2028 (USD Million)
- 1.2.2. AI-based Clinical Trials Solution Provider Market, by Clinical Trial Phase, 2020-2028 (USD Million)
- 1.2.3. AI-based Clinical Trials Solution Provider Market, by Application, 2020-2028 (USD Million)
- 1.2.4. AI-based Clinical Trials Solution Provider Market, by End-use, 2020-2028 (USD Million)
- 1.3. Key Trends
- 1.4. Estimation Methodology
- 1.5. Research Assumption
Chapter 2. Global AI-based Clinical Trials Solution Provider Market Definition and Scope
- 2.1. Objective of the Study
- 2.2. Market Definition & Scope
- 2.2.1. Scope of the Study
- 2.2.2. Industry Evolution
- 2.3. Years Considered for the Study
- 2.4. Currency Conversion Rates
Chapter 3. Global AI-based Clinical Trials Solution Provider Market Dynamics
- 3.1. AI-based Clinical Trials Solution Provider Market Impact Analysis (2020-2028)
- 3.1.1. Market Drivers
- 3.1.1.1. Increase in the number of clinical studies
- 3.1.1.2. Growing penetration of the AI-based platforms for enhancing efficiency and productivity of trials at many stages
- 3.1.2. Market Challenges
- 3.1.2.1. Lack of AI accuracy in clinical practices
- 3.1.2.2. Imposition of several stringent regulations on the approval of AI-based clinical trials hinders
- 3.1.3. Market Opportunities
- 3.1.3.1. Rising R&D investments in various therapeutic areas
- 3.1.3.2. Growing awareness and diversified applications of artificial intelligence (AI) in the field of clinical trials
Chapter 4. Global AI-based Clinical Trials Solution Provider Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2028)
- 4.2. PEST Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.3. Investment Adoption Model
- 4.4. Analyst Recommendation & Conclusion
- 4.5. Top investment opportunity
- 4.6. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
- 5.1.1. Assessment of the overall impact of COVID-19 on the industry
- 5.1.2. Pre COVID-19 and post COVID-19 market scenario
Chapter 6. Global AI-based Clinical Trials Solution Provider Market, by Clinical Trial Phase
- 6.1. Market Snapshot
- 6.2. Global AI-based Clinical Trials Solution Provider Market by Clinical Trial Phase, Performance - Potential Analysis
- 6.3. Global AI-based Clinical Trials Solution Provider Market Estimates & Forecasts by Clinical Trial Phase, 2018-2028 (USD Million)
- 6.4. AI-based Clinical Trials Solution Provider Market, Sub Segment Analysis
- 6.4.1. Phase-I
- 6.4.2. Phase-II
- 6.4.3. Phase-III
Chapter 7. Global AI-based Clinical Trials Solution Provider Market, by Application
- 7.1. Market Snapshot
- 7.2. Global AI-based Clinical Trials Solution Provider Market by Application, Performance - Potential Analysis
- 7.3. Global AI-based Clinical Trials Solution Provider Market Estimates & Forecasts by Application, 2018-2028 (USD Million)
- 7.4. AI-based Clinical Trials Solution Provider Market, Sub Segment Analysis
- 7.4.1. Oncology
- 7.4.2. Cardiovascular Diseases
- 7.4.3. Neurological Diseases or Conditions
- 7.4.4. Infectious Diseases
- 7.4.5. Others
Chapter 8. Global AI-based Clinical Trials Solution Provider Market, by End-use
- 8.1. Market Snapshot
- 8.2. Global AI-based Clinical Trials Solution Provider Market by End-use, Performance - Potential Analysis
- 8.3. Global AI-based Clinical Trials Solution Provider Market Estimates & Forecasts by End-use, 2018-2028 (USD Million)
- 8.4. AI-based Clinical Trials Solution Provider Market, Sub Segment Analysis
- 8.4.1. Pharmaceutical Companies
- 8.4.2. Academia
- 8.4.3. Others
Chapter 9. Global AI-based Clinical Trials Solution Provider Market, Regional Analysis
- 9.1. AI-based Clinical Trials Solution Provider Market, Regional Market Snapshot
- 9.2. North America AI-based Clinical Trials Solution Provider Market
- 9.2.1. U.S. AI-based Clinical Trials Solution Provider Market
- 9.2.1.1. Clinical Trial Phase breakdown estimates & forecasts, 2018-2028
- 9.2.1.2. Application breakdown estimates & forecasts, 2018-2028
- 9.2.1.3. End-use breakdown estimates & forecasts, 2018-2028
- 9.2.2. Canada AI-based Clinical Trials Solution Provider Market
- 9.3. Europe AI-based Clinical Trials Solution Provider Market Snapshot
- 9.3.1. U.K. AI-based Clinical Trials Solution Provider Market
- 9.3.2. Germany AI-based Clinical Trials Solution Provider Market
- 9.3.3. France AI-based Clinical Trials Solution Provider Market
- 9.3.4. Spain AI-based Clinical Trials Solution Provider Market
- 9.3.5. Italy AI-based Clinical Trials Solution Provider Market
- 9.3.6. Rest of Europe AI-based Clinical Trials Solution Provider Market
- 9.4. Asia-Pacific AI-based Clinical Trials Solution Provider Market Snapshot
- 9.4.1. China AI-based Clinical Trials Solution Provider Market
- 9.4.2. India AI-based Clinical Trials Solution Provider Market
- 9.4.3. Japan AI-based Clinical Trials Solution Provider Market
- 9.4.4. Australia AI-based Clinical Trials Solution Provider Market
- 9.4.5. South Korea AI-based Clinical Trials Solution Provider Market
- 9.4.6. Rest of Asia Pacific AI-based Clinical Trials Solution Provider Market
- 9.5. Latin America AI-based Clinical Trials Solution Provider Market Snapshot
- 9.5.1. Brazil AI-based Clinical Trials Solution Provider Market
- 9.5.2. Mexico AI-based Clinical Trials Solution Provider Market
- 9.6. Rest of The World AI-based Clinical Trials Solution Provider Market
Chapter 10. Competitive Intelligence
- 10.1. Top Market Strategies
- 10.2. Company Profiles
- 10.2.1. Unlearn.AI, Inc.
- 10.2.1.1. Key Information
- 10.2.1.2. Overview
- 10.2.1.3. Financial (Subject to Data Availability)
- 10.2.1.4. Product Summary
- 10.2.1.5. Recent Developments
- 10.2.2. Saama Technologies
- 10.2.3. Antidote Technologies, Inc.
- 10.2.4. Innoplexus
- 10.2.5. Mendel.ai
- 10.2.6. Median Technologies
- 10.2.7. Symphony AI
- 10.2.8. BioAge Labs, Inc.
- 10.2.9. AiCure, LLC
- 10.2.10. Halo Health Systems
Chapter 11. Research Process
- 11.1. Research Process
- 11.1.1. Data Mining
- 11.1.2. Analysis
- 11.1.3. Market Estimation
- 11.1.4. Validation
- 11.1.5. Publishing
- 11.2. Research Attributes
- 11.3. Research Assumption